Amylyx is a pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases.

Register for Details

For more details on financing and valuation for Amylyx, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Amylyx

Forge green plus iconForge green minus icon

What is Amylyx's IPO price?

Amylyx's IPO price is $14.88 as of 1/18/24.
Forge green plus iconForge green minus icon

What is Amylyx's funding to date?

Amylyx has raised $203.25MM to date.
Forge green plus iconForge green minus icon

When was Amylyx founded?

Amylyx was founded in 2014.

Amylyx Funding Rounds and Last Known Valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation
7/20/2021 Series C-1 and C-2 $135MM raised $XXX.XX $XXX.XX
7/1/2020 Series B $60.52MM raised $XXX.XX $XXX.XX
8/23/2016 Series A $7.73MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: Apr 17, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.